Amarin Corporation ( NASDAQ: AMRN ) announced that its commercial partner in Mainland China, EddingPharm received regulatory approval for VASCEPA from China’s National Medical Products Administration. Shares of AMRN up 2% premarket. NMPA granted approval for VASCEPA to reduce the risk of cardiovascular events as an adjunct to statin therapy in adult patients with elevated and high triglycerides and established cardiovascular disease or diabetes mellitus with ≥2 other cardiovascular disease risk factors, combined with hypertriglyceridemia.
Following approval by NMPA, EDDING is working to include VASCEPA on the National Reimbursement Drug Listing and augment the ongoing commercial launch of VASCEPA in China to include the CVRR indication. Source: Press Release More on Amarin Amarin Corporation plc (AMRN) Q1 2024 Earnings Call Transcript Amarin Corporation: Small Signs Of Recovery May Not Be Enough Amarin falls on CEO exit and Vascepa coverage update Amarin Q1 2024 Earnings Preview Seeking Alpha’s Quant Rating on Amarin.
